Related Experiment Video
Updated: Jun 6, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Ischemia modified albumin changes - review and clinical implications
Eftihia Sbarouni1, Panagiota Georgiadou, Vassilis Voudris
12nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. esbarouni@yahoo.gr
Ischemia modified albumin (IMA) shows promise for early ischemia detection. This biomarker may aid in diagnosing acute coronary syndromes (ACS) alongside traditional methods.
Area of Science:
- Cardiology
- Biochemistry
Background:
- Ischemia modified albumin (IMA) is a potential biomarker for detecting ischemia.
- Early detection of ischemia is crucial to prevent irreversible cardiac injury.
Purpose of the Study:
- To review available information on IMA, including its pathophysiology, analysis, clinical applications, and future perspectives.
- To assess the utility of IMA in the diagnostic window for acute coronary syndromes (ACS).
Main Methods:
- Literature search of MEDLINE using terms: IMA, biomarkers, and ischemia.
- Review of existing data on IMA's role in cardiac diagnostics.
Main Results:
- IMA is a promising biomarker for early ischemia detection before irreversible damage.
- IMA may complement electrocardiogram and cardiac troponins in diagnosing ACS in the Emergency Department.
Conclusions:
- IMA holds potential for early ischemia detection and ACS diagnosis.
- Further research is needed to establish IMA's prognostic significance in ACS and post-revascularization.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Drug Distribution: Plasma Protein Binding
